Bristol-Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City, develops and market innovative medicines for various disorders. BMS in its present form was formed in 1989, following the merger of its predecessors Bristol-Myers and the Squibb Corporation.
- In Aug 2020, Bristol Myers Squibb acquired Forbius, Inc. for its TGF-beta program, including its lead investigation asset AVID200, currently in clinical development for oncology and fibrosis. Financial details remains undisclosed.
- In Apr 2019, BMS acquired Celgene in $74 billion and make it, its a wholly owned subsidiary.
- In Mar 2018, BMS acquired IFM Therapeutics in $300 Mn upfront with potential of up to $1.01 billion in milestones and gains full rights to IFM’s preclinical STING and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer.
- In Feb 2015, BMS acquired Flexus Biosciences, in a deal size of upto $1.25 billion, including $800 Mn upfront and up to $450 Mn in development milestones. With this deal BMS gains full rights to Flexus’ lead preclinical IDO1 inhibitor F001287 and the company’s broad IDO/TDO discovery program.
- In Sept 2010, ZymoGenetics Inc, developing an Interleukin-21 targeting melanoma, was acquired by BMS for $885 Mn USD.
- In Sep 2009, Medarex Inc, developing mAbs for cancer, autoimmune & infectious diseases was acquired by BMS in $2.4 billion USD.
- In May 2008, BMS acquired Kosan Biosciences, an oncology driven pharmaceutical company having two important classes of anticancer agents: novel Hsp90 (heat shock protein 90) inhibitors and epothilones, for $190 Mn USD.
- In Sept 2007, BMS acquired Adnexus Therapeutics, in approx $505 Mn USD, and make its wholly owned subsidiary. With Adnexus’ proprietary protein design engine, PROfusion™, trillions of protein variations can be engineered at one time.
Celgene Acquisitions – - In Jan 2018, Juno Therapeutics was acquired by Celgene for $9 billion developing CAR T immunotherapies.
- In Jan 2018, Celgene acquired Impact Biomedicines, for up to $7 billion adding Fedratinib to Its pipeline of novel therapies for Hematologic Malignancies.
- In Apr 2015, Celegene acquired Quanticel Pharmaceuticals, a private drug discovery company having proprietary platform for the single-cell genomic analysis of human cancer.
- In Jan 2012, Celgene acquired Avila Therapeutics in approx. $900 Mn, having Bruton’s tyrosine kinase inhibitor in its portifolio.
- In Jan 2010, Celgene acquired Gloucester Pharma in approx. $630 Mn USD and added Istodax® to its portfolio through this acquisition.
- In 2010, Celgene acquired Abraxis BioScience in approx. $2.9 Billion USD, adding Abraxane® to its portfolio. Abraxane® is a protein-bound injectable formulation of paclitaxel, and was approved by FDA in 2005 for breast cancer cases where cancer did not respond to other chemotherapy.
- In 2008, Celgene acquired Pharmion Corporation in $2.9 Billion USD. Pharmion was having marketing and developmental rights of Amrubicin (in licensed from Dainippon Sumitomo) for US & Europe in its portfolio.
Page 1 of 3
